Barinthus Biotherapeutics (BRNS) Retained Earnings (2020 - 2026)

Barinthus Biotherapeutics has reported Retained Earnings for 7 years, with the latest figure at -$309.6 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 20.33% year-over-year to -$309.6 million; the trailing twelve-month figure through Mar 2026 stood at -$309.6 million (down 20.33% YoY), and the FY2025 full-year result was -$304.1 million, down 27.95% from the prior year.
• Retained Earnings for Q1 2026 stood at -$309.6 million, down from -$304.1 million in the prior quarter.
• The five-year high for Retained Earnings was -$82.1 million in Q3 2022, with the low at -$309.6 million in Q1 2026.
• Historically, Retained Earnings has averaged -$193.1 million across 5 years, with a median of -$192.1 million in 2024.
• Annual changes were most pronounced in 2022 — Retained Earnings rose 12.22% — and 2023, when it slumped 94.14%.
• Barinthus Biotherapeutics' Retained Earnings stood at -$103.2 million in 2022, then tumbled by 71.04% to -$176.6 million in 2023, then plunged by 34.59% to -$237.7 million in 2024, then fell by 27.95% to -$304.1 million in 2025, then declined by 1.82% to -$309.6 million in 2026.
• The last three Retained Earnings figures came in at -$309.6 million (Q1 2026), -$304.1 million (Q4 2025), and -$293.0 million (Q3 2025), per Business Quant data.